These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 15379638)
21. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Mascelli MA; Lance ET; Damaraju L; Wagner CL; Weisman HF; Jordan RE Circulation; 1998 May; 97(17):1680-8. PubMed ID: 9591761 [TBL] [Abstract][Full Text] [Related]
22. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495 [TBL] [Abstract][Full Text] [Related]
23. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro. Hamilton SF; Miller MW; Thompson CA; Dale GL J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176 [TBL] [Abstract][Full Text] [Related]
25. Comparative pharmacology of GP IIb/IIIa antagonists. Schrör K; Weber AA J Thromb Thrombolysis; 2003 Apr; 15(2):71-80. PubMed ID: 14618072 [TBL] [Abstract][Full Text] [Related]
26. The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. Stringer KA Ann Pharmacother; 1999 Jun; 33(6):712-22. PubMed ID: 10410186 [TBL] [Abstract][Full Text] [Related]
28. Studies on the binding of 3H-SR121566, an inhibitor of Gp IIb-IIIa activation. Savi P; Zamboni G; Rescanières O; Herbert JM Thromb Haemost; 2001 Apr; 85(4):702-9. PubMed ID: 11341508 [TBL] [Abstract][Full Text] [Related]
29. Ability of different glycoprotein IIb-IIIa ligands to support platelet aggregation induced by activating antibody CRC54. Naimushin YA; Mazurov AV Biochemistry (Mosc); 2005 Jul; 70(7):782-9. PubMed ID: 16097942 [TBL] [Abstract][Full Text] [Related]
30. [GP IIb/IIIa receptor antagonists--molecular and clinical aspects]. Francuz T Postepy Hig Med Dosw; 2001; 55(3):419-32. PubMed ID: 11505641 [TBL] [Abstract][Full Text] [Related]
31. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention. Cheng JW Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710 [TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Kereiakes DJ; Kleiman NS; Ferguson JJ; Masud AR; Broderick TM; Abbottsmith CW; Runyon JP; Anderson LC; Anders RJ; Dreiling RJ; Hantsbarger GL; Bryzinski B; Topol EJ Circulation; 1998 Sep; 98(13):1268-78. PubMed ID: 9751674 [TBL] [Abstract][Full Text] [Related]
34. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Silva MA; Donovan JL; Gandhi PJ; Volturo GA Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468 [TBL] [Abstract][Full Text] [Related]
35. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation. Straub A; Wendel HP; Azevedo R; Ziemer G Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360 [TBL] [Abstract][Full Text] [Related]
36. GP IIb/IIIa blockade during peripheral artery interventions. Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207 [TBL] [Abstract][Full Text] [Related]
37. PlA(1)/PlA(2) polymorphism does not influence response to Gp IIb-IIIa inhibitors in patients undergoing coronary angioplasty. Verdoia M; Pergolini P; Camaro C; Restifo M; Rolla R; Schaffer A; Di Giovine G; Marino P; Bellomo G; Suryapranata H; De Luca G; Blood Coagul Fibrinolysis; 2013 Jun; 24(4):411-8. PubMed ID: 23412353 [TBL] [Abstract][Full Text] [Related]
38. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Tcheng JE Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845 [TBL] [Abstract][Full Text] [Related]
39. Effects of GP IIb/IIIa inhibitors on vascular inflammation, coronary microcirculation, and platelet function. Kereiakes DJ Rev Cardiovasc Med; 2006; 7 Suppl 4():S3-11. PubMed ID: 17224889 [TBL] [Abstract][Full Text] [Related]
40. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future. De Luca G; Savonitto S; van't Hof AW; Suryapranata H Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]